TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity after cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score for the sensory component of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bioequivalence based on AUCf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence based on AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence based on Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language development assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve from timepoint 0 to t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve from timepoint 0 to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of intradialytic hypotensive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of patients that prefer flavored contrast
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bowel diameter measurements on MR Enterography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Positive Detection Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Incidence of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fear of falling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Objective Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTBS Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline of limb volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25 (OH) vitamin D blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MNA Maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to plasma MNA Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma MNA concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutoff value of CTC counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard quantification variables from 3D PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of SR exenatide
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of SR exenatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days of illness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Safety and tolerability of MKC253 Inhalation Powder
Endpoint domain: Adverse events/effects
Primary endpoint: motor and sensory nerve conduction studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cross-sectional area (CSA) of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Curve (AUC) of Plasma Total GLP-1 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: long-term survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Weight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole body palmitate and carbohydrate oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shoulder tip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: portal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hepatic arterial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hepatic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Comparison of in-vivo tissue characterization with ex-vivo histocytopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of novel CD33-targeting immunoconjugate agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of confirmed or severe hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with acute & subacute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: haemoglobin (Hb) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Scale on Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CYP2D6 duplication or polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth - weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopment - Bayley Scale of Infant and Toddler Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADHDRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in size of evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain sensitivity profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of 3D TVU and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Fugl-Meyer Assessment Test (upper extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Chedoke Arm and Hand Activity Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VAS Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SANE score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Goal Attainment Scale (GAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Revised Knox Preschool Play Scale (RKPPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vineland Adaptive Behavior Scale-Chinese version (VABS-C)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Participants With Any Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Chemistry Parameters Outside the Normal Reference Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Clinical Chemistry Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decline in transferrin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Yearly change in chest CT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average plasma glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in diabetes self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects achieving 7% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: drug plasma levels midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug plasma levels rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug plasma levels flurbiprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semaphorin levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Smoking Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Corneal health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygenation readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Testosterone Average Concentration in the Normal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Severe Mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Number Who Discontinued Medication Within First 6 Study Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Volume of sweat from pilocarpine-induced sweat test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral fat level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Olfactory and taste dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety from baseline to follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in depression from baseline to follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Glutathione (GSH) from baseline to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TBARS from baseline to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of intrusive memories of trauma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Major or Clinically Relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Best overall response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ability to deliver a full course of MRI-guided SBRT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in PaO2/FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of adequate colon cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Health-related Quality of Life (QoL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Intradialytic mass transfer coefficient of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients that consent to participate in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: proportion of included patients that will complete the evaluations at baseline, 6 months and 12 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Remaining overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Demonstration of non-caseating granulomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Sleep Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Pharmacokinetic profile of radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excretion rate and cumulative excretion of radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of parent YM178
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of Grade 3-4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of MSM under PrEP among eligible HIV-seronegative participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence rate of HIV infection
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of adherence reported by MSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Health Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complications of therapeutic mammoplasty
Endpoint domain: Adverse events/effects
Primary endpoint: Delay in the start of adjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retinal redetachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Child Abuse Potential Inventory (B-CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Journal records: further reports on abuse or violence
Endpoint domain: Adverse events/effects
Primary endpoint: Measurable oxidant stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression-Free Survival (PFS) ratio at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marked improvement in clinical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: marked improvement in endoscopic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: marked improvement in histological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numbers of episodes of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of nausea (in hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of nausea as per Edmonton's Symptom Assessment System (ESAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of Alvocidib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients achieving clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common bile duct diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence Rate of Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction, Life-threatening Bleeding Events and Vascular Death)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence Rate of Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Incidence Rate of Life-threatening Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virologic Response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average interstitial lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful new vascularization of internal-to-external cerebral collateral flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quantity of urine lost over a 7-day period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine lost on stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Alcohol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Field Gain in Degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Failure of peribulbar block
Endpoint domain: Adverse events/effects
Primary endpoint: Number of grade 3-5 adverse events related to CP infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of lung oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes of lung compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced expiratory volume in 1 second (FEV1) including reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Vital Capacity (FVC) including reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway hyper-reactivity (methacholine test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: C.S rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of intraoperative cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: neurologic outcome of patients according to Cerebral performance category scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse Events That Meet Dose-limiting Toxicity Criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Activities-Specific Balance Confidence test (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Berg Balance Scale (BBS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Single Leg Stance (SLS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timed Up and Go (TUG)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of emergence agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of chlamydial DNA in rectal and vaginal specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of true rectal chlamydial infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Grade of discomfort and willingness to undergo rectal sampling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shock index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of isometric trunk muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of low back pain disability as measured by the Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Embryo potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Orthostatic Hypotension Questionnaire Score (OHQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virologic response (SVR) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fetal hemoglobin level after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total anti oxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responders to serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes